Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge

European Annals of Allergy and Clinical Immunology

Volumn 36, Issue 4, 2004, Pages 146-150

  Ciprandi, Giorgio ^a   Cirillo, Ignazio ^b   Vizzaccaro, Andrea ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Navy Hospital   (Italy)

Author keywords

Allergic inflammation; Cytokines; Early phase; Fexofenadine; Mizolastine; Nasal challenge

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CYTOKINE; FEXOFENADINE; INTERLEUKIN 1; INTERLEUKIN 6; MIZOLASTINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; INFLAMMATION; NASAL PRURITUS; NOSE OBSTRUCTION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINGLE DRUG DOSE; SNEEZING; SYMPTOMATOLOGY;

ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; NASAL PROVOCATION TESTS; PARIETARIA; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TERFENADINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342464076     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Naclerio R.-M., Meier H.-L., Kagey-Sobotka A. - Mediator release after nasal airway challenge with allergen. Am. Rev. Resp. Dis. 1983;128:597-602.
2. Ciprandi G., Pronzato C., Ricca V. et al. - Evidence of ICAM-1 expression on nasal epithelial cells in acute rhinoconjunctivitis due to pollen exposure. J. Allergy Clin. Immunol. 1994;4:738-46.
3. Ciprandi G., Pronzato C., Ricca V. et al. - Allergen-specific challenge induces intercellular adhesion molecule-1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects: relationships with early and late inflammatory phenomena. Am. J. Resp. Crit. Care Med. 1994;150:1653-59.
4. Mygind N., Dahl R. - Challenge tests in nose and bronchi: pharmacological modulation of rhinitis and asthma. Clin. Exp. Allergy 1996;26 (3):39-43.
5. Howarth P.-H. - The cellular basis for allergic rhinitis. Allergy 1995;50(23):6-10.
6. Colderon E, Lockey RF A possible role for adhesion molecules in asthma. J. Allergy Clin. Immunol. 1995;90:852-65.
7. Metcalfe D.-D., Baram D., Mekori Y.-A. - Mast cells. Physiol Rev 1997;77:1033-79.
8. Lippert U., Moller A., Welker P. et al. - Inhibition of cytokine secretion from human leukemic most cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9:118-24.
9. Carayol N., Crampette L., Mainprice B. et al. - Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy 2002;57:1067-70.
10. Triggiani M., Gentile M., Secondo A. et al. - Histamine induces exocytosis and IL6 production from human lung macrophages through interaction with H1-receptors. J Immunol 2001;166: 4083-91.
11. Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2002;57:841-55.
12. Church M.-K. - H1-antihistamines and inflammation. Clin Exp Allergy 2001;31:1341-3.
13. Benavides J., Schoemaker H., Dana C. et al. - In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung 1995;45:551-8.
14. Yamada N. - Effects of mizolastine on the infiltration of easinophils. Jap Pharmacol Ther 1998;26:145-50.
15. Sudo K., Nagai K., Yamada N. - Inhibitory effect of mizolastine on 5-lypoxygenase. Jap Pharmacol Ther 1998;26:155-7.
16. Funayama K., Honda K, Yamada N. - Inhibitory effects of mizolastine on cytokine productions. Jap Pharmacol Ther 1998;26:139-43.
17. Grundmann J.-U., Bockelmann R., Bonnekoh B. et al. - UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin. Photochem Photobiol 2001;74:587-92.
18. Abdelaziz M.-M., Devalia J.-L., Khair O.-A. et al. - Effect of fexofenadine on easinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20.
19. Hirono T. - Interleukin 6 and its receptors: ten years later. Int Rev Immunol 1998;16:249-71.
20. Saito H.-M., Ebisava H., Tachimoto M. et al. - Selective growth of human mast cells induced by Steel factor, IL6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 1996;157: 343-52.
21. Tang C.-J., Rolland C., Ward X. et al. - Modulatory effects of alveolar macrophages on CD4+ T-cell IL5 responses correlate with IL1, IL6 and IL12 production. Eur Resp J 1999;114:106-13.
22. Takiwaza H.-T., Ohtoshi N., Yamashita T. et al. - IL6 receptor expression on human bronchial epithelial cells: regulation by IL1 and IL6. Am J Physiol 1996;270:346-55.
23. Bousquet J. - Rapid symptom relief in rhinitis. Clin Exp Allergy 1999;29(Suppl 1):25-9.
24. Allocco F.-T., Votypka V., deTinea M. et al. - Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol 2002;89:578-84
25. Bensch G.-W., Nelson H.-S., Borish L.-C. - Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann Allergy Asthma Immunol 2002;88:457-62.
26. Bachert C., Brostoff J., Scadding G.-K. et al. - Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. Allergy 1998;53:969-75.